David Stamler

2.3k total citations
46 papers, 952 citations indexed

About

David Stamler is a scholar working on Neurology, Pharmaceutical Science and Cellular and Molecular Neuroscience. According to data from OpenAlex, David Stamler has authored 46 papers receiving a total of 952 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Neurology, 12 papers in Pharmaceutical Science and 11 papers in Cellular and Molecular Neuroscience. Recurrent topics in David Stamler's work include Chemical Reactions and Isotopes (12 papers), Attention Deficit Hyperactivity Disorder (7 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). David Stamler is often cited by papers focused on Chemical Reactions and Isotopes (12 papers), Attention Deficit Hyperactivity Disorder (7 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). David Stamler collaborates with scholars based in United States, Israel and Austria. David Stamler's co-authors include Joohi Jimenez‐Shahed, David Shprecher, William G. Ondo, Hubert H. Fernandez, Stewart A. Factor, Robert A. Hauser, Mat D. Davis, Margaret Bradbury, L. Fredrik Jarskog and Paul H. Edelstein and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Neurology.

In The Last Decade

David Stamler

42 papers receiving 911 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Stamler United States	17	365	221	214	132	132	46	952
Susan M. Cheer New Zealand	18	30 0.1×	70 0.3×	157 0.7×	136 1.0×	165 1.3×	30	1.1k
Silvia Boschi Italy	15	47 0.1×	47 0.2×	91 0.4×	105 0.8×	62 0.5×	46	685
Bruce H. Phelps United States	21	79 0.2×	119 0.5×	277 1.3×	160 1.2×	77 0.6×	42	1.7k
Peter S. Mueller United States	16	125 0.3×	88 0.4×	240 1.1×	173 1.3×	62 0.5×	34	1.0k
J. H. Tyrer Australia	18	193 0.5×	117 0.5×	266 1.2×	131 1.0×	96 0.7×	58	1.1k
A. Fiorentini Italy	14	39 0.1×	99 0.4×	432 2.0×	66 0.5×	38 0.3×	31	841
Laurent M. Willems Germany	24	124 0.3×	602 2.7×	1.2k 5.5×	104 0.8×	38 0.3×	88	1.7k
Fahad S. Alshehri Saudi Arabia	17	51 0.1×	189 0.9×	39 0.2×	144 1.1×	32 0.2×	64	874
Margaret G. Northway United States	10	261 0.7×	94 0.4×	48 0.2×	62 0.5×	91 0.7×	16	631
Takuro Sugai Japan	19	32 0.1×	57 0.3×	386 1.8×	132 1.0×	63 0.5×	63	862

Countries citing papers authored by David Stamler

Since Specialization

Citations

This map shows the geographic impact of David Stamler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Stamler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Stamler more than expected).

Fields of papers citing papers by David Stamler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Stamler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Stamler. The network helps show where David Stamler may publish in the future.

Co-authorship network of co-authors of David Stamler

This figure shows the co-authorship network connecting the top 25 collaborators of David Stamler. A scholar is included among the top collaborators of David Stamler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Stamler. David Stamler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frank, Samuel, Karen E. Anderson, Hubert H. Fernandez, et al.. (2024). Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease. Neurology and Therapy. 13(3). 655–675. 3 indexed citations

Jankovic, Joseph, Barbara J. Coffey, Daniel O. Claassen, et al.. (2023). Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study. Movement Disorders Clinical Practice. 10(9). 1388–1398. 7 indexed citations

Heras‐Garvin, Antonio, et al.. (2021). ATH434 Reduces α‐Synuclein‐Related Neurodegeneration in a Murine Model of Multiple System Atrophy. Movement Disorders. 36(11). 2605–2614. 16 indexed citations

Stamler, David, et al.. (2021). The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers. European Journal of Clinical Pharmacology. 78(1). 11–18. 5 indexed citations

Jankovic, Joseph, Barbara J. Coffey, Daniel O. Claassen, et al.. (2020). 152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents. CNS Spectrums. 25(2). 297–297. 1 indexed citations

Frank, Samuel, Christina Vaughan, David Stamler, et al.. (2020). Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease (4310). Neurology. 94(15_supplement).

Stamler, David, Margaret Bradbury, Cynthia S. Wong, & Elliot Offman. (2019). A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation (S4.001). Neurology. 92(15_supplement). 13 indexed citations

Finkelstein, David I., Nadia Stefanova, Paul A. Adlard, Margaret Bradbury, & David Stamler. (2019). PBT434 Prevents α-synuclein Aggregation, Neuron Loss, Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic Mouse Model of Multiple System Atrophy (P5.8-006). Neurology. 92(15_supplement). 3 indexed citations

Fernandez, Hubert H., David Stamler, Mat D. Davis, et al.. (2019). Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. Journal of Neurology Neurosurgery & Psychiatry. 90(12). jnnp–2018. 43 indexed citations

10.

Fernandez, Hubert H., David Stamler, Mat D. Davis, et al.. (2018). Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study (P4.075). Neurology. 90(15_supplement). 1 indexed citations

11.

Cox, Donna S., et al.. (2018). Cardiovascular Safety Assessment of Deutetrabenazine in Healthy Volunteers and Implications for Patients With Huntington Disease or Tardive Dyskinesia (P4.080). Neurology. 90(15_supplement).

12.

Claassen, Daniel O., Benjamin Carroll, Eric Q. Wu, et al.. (2017). Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. PubMed. 4(1). 3–3. 74 indexed citations

13.

Jimenez‐Shahed, Joohi, Hubert H. Fernandez, David Stamler, et al.. (2017). Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia (TD) (P2.016). Neurology. 88(16_supplement). 2 indexed citations

14.

Anderson, Karen E., David Stamler, Mat D. Davis, et al.. (2017). Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Psychiatry. 4(8). 595–604. 134 indexed citations

15.

Stamler, David, et al.. (2016). A Relative Bioavailability Study of Three Dose Strengths and Four Dose Levels of SD-809, a Potential Treatment for Movement Disorders (P1.054). Neurology. 86(16_supplement). 3 indexed citations

16.

Dowling, Ariel V., David Stamler, Cynthia Wong, et al.. (2016). Wearable Sensors in Huntington Disease: A Pilot Study. Journal of Huntington s Disease. 5(2). 199–206. 51 indexed citations

17.

Nance, Patricia W., et al.. (2011). Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury. Spinal Cord. 49(9). 974–980. 7 indexed citations

18.

Stone, Gregory G., Dee Shortridge, Robert K. Flamm, et al.. (1997). PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin. Epidemiology and Infection. 118(2). 119–124. 13 indexed citations

19.

Vetter, N, David Stamler, Sean O’Neill, et al.. (1997). Clarithromycin vs Combined Cefuroxime and Erythromycin in the Treatment of Hospitalised Community-Acquired Pneumonia Patients - Intravenous Followed by Oral Therapy. Clinical Drug Investigation. 14(6). 439–449. 6 indexed citations

20.

Wurzer, H, Luı́s Rodrigo, David Stamler, et al.. (1997). Short‐course therapy with amoxycillin–clarithromycin triple therapy for 10 days (ACT‐10) eradicates Helicobacter pylori and heals duodenal ulcer. Alimentary Pharmacology & Therapeutics. 11(5). 943–952. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact